Cargando…
Effect of dapagliflozin on diabetic patients with cardiovascular disease via MAPK signalling pathway
Clinical studies have shown that dapagliflozin can reduce cardiovascular outcome in patients with type 2 diabetes mellitus (T2DM), but the exact mechanism is unclear. In this study, we used the molecular docking and network pharmacology methods to explore the potential mechanism of dapagliflozin on...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335696/ https://www.ncbi.nlm.nih.gov/pubmed/34258872 http://dx.doi.org/10.1111/jcmm.16786 |